openPR Logo
Press release

Chronic Idiopathic Constipation Treatment Market is Predicted to Procure USD 19.7 Bn by 2033, Grow at a CAGR of 7.5% | Fact.MR

05-21-2024 06:15 AM CET | Health & Medicine

Press release from: Fact.MR

Chronic Idiopathic Constipation Treatment Market

Chronic Idiopathic Constipation Treatment Market

According to Fact.MR, a market research and competitive intelligence company, the global chronic idiopathic constipation treatment market is worth $9.4 billion in 2023 and is expected to grow at a 7.5% CAGR from 2023 to 2033.

Chronic idiopathic constipation (CIC) is a type of constipation that lasts a long period and has no clear explanation. It is a widespread condition that affects a large proportion of the global population, with a higher frequency among the elderly.

The chronic idiopathic constipation treatment market is predicted to expand significantly in the future years. The market is being driven by the rising prevalence of CIC, more awareness of the ailment, and growing need for effective treatment alternatives.

Get Free Sample Report to Grow Your Profit Margin:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8517

Furthermore, the aging population, sedentary lifestyles, and dietary changes are all contributing to the growing burden of CIC, driving up demand for therapeutic solutions.

Fiber supplements, laxatives, stool softeners, and prokinetic drugs are popular pharmaceuticals used to control CIC. Furthermore, advances in digital health technology are influencing the future of chronic idiopathic constipation treatment. Mobile software, wearable gadgets, and remote monitoring technologies are being developed to assist patients in tracking their bowel movements, nutrition, and exercise routines, as well as providing individualized management recommendations for CIC.

Key Takeaways from Market Study

Global sales of chronic idiopathic constipation medications are estimated to reach $19.7 billion by 2033.
The US market is rapidly developing due to the presence of important industry players.
The increasing frequency of chronic idiopathic constipation among Japan's elderly population is driving up demand for chronic idiopathic constipation treatment treatments.
Germany is likely to be a lucrative market for chronic idiopathic constipation medicine makers due to its excellent healthcare infrastructure.

"Key market participants are working to create cutting-edge solutions that can deliver effective and safe treatment for chronic idiopathic constipation sufferers," says a Fact.MR analyst.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8517

Competitive Landscape

According to Fact.MR, a market research and competitive intelligence firm, key players in the chronic idiopathic constipation treatment market are focusing on developing technologically advanced solutions, introducing new design products, obtaining regulatory clearances, and partnering with and acquiring other companies.

Leading businesses in the chronic idiopathic constipation treatment industry are currently seeking FDA clearance for newly developed drugs. Over the forecast period, obtaining FDA approval is expected to be one of the important focus areas for manufacturers of chronic idiopathic constipation drugs.

The FDA has just given the all-clear to several medications.

In February 2020, the FDA approved an osmotic laxative developed by Braintree Laboratories (Sebela) to treat adults with persistent idiopathic constipation.
In April 2020, Ironwood Pharmaceuticals, Inc. announced that the USPTO has issued certificates of approval for patent applications relating to the formulation of the 72 mcg dose of LINZESS.
In March 2020, the US Food and Drug Administration granted Sebela Pharmaceuticals, Inc. approval to market Pizensy (lactitol).

Recent Market Developments

In Japan, EA Pharma and Mochida Pharmaceutical introduced the successful chronic constipation drug 'Movicol HD' in May 2022.

In April 2022, the United States Food and Drug Administration (USFDA) authorized Ibsrela, a drug made by Ardelyx, Inc. This NHE3 inhibitor is prescribed to adult patients with IBS-C (irritable bowel syndrome with constipation).

Chronic Idiopathic Constipation Treatment Industry Research Segmentation

By Type:
Normal-transit Constipation
Slow-transit Constipation
By Therapy:
Pharmacological Therapies
Non-pharmacological Therapies
By Treatment:
Medication
Surgery
By Drug:
Serotonin-4 (5-Ht4) Receptor Agonist
Guanylate Cyclase-C Agonist
Laxatives
Stimulants
By Route of Administration:
Oral
Injectable
By End User:
Hospitals
Homecare
Specialty Clinics
By Region:
North America
Latin America
Europe
East Asia
South Asia & Oceania
MEA

๐‘๐ž๐š๐ ๐Œ๐จ๐ซ๐ž: https://www.factmr.com/report/chronic-idiopathic-constipation-treatment-market

More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global chronic idiopathic constipation treatment market, presenting historical demand data (2018 to 2022) and forecast statistics for the period (2023 to 2033).

The study divulges essential insights on the market based on type (normal-transit constipation, slow-transit constipation), therapy (pharmacological therapies, non-pharmacological therapies), treatment (medication, surgery), drug (serotonin-4 (5-Ht4) receptor agonist, guanylate cyclase-C agonist, laxatives, stimulants), route of administration (oral, injectable), and end user (hospitals, homecare, specialty clinics), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).

๐‚๐จ๐ง๐ญ๐š๐œ๐ญ:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

๐€๐›๐จ๐ฎ๐ญ ๐…๐š๐œ๐ญ.๐Œ๐‘

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Idiopathic Constipation Treatment Market is Predicted to Procure USD 19.7 Bn by 2033, Grow at a CAGR of 7.5% | Fact.MR here

News-ID: 3504763 • Views: โ€ฆ

More Releases from Fact.MR

Stain-Resistant Coatings Market Fuels Growth in Architectural and Transportation Sectors
Stain-Resistant Coatings Market Fuels Growth in Architectural and Transportation โ€ฆ
The global stain resistant coatings market has rapidly evolved into a dynamic and expansive segment within the broader coatings industry. As of 2023, this market is valued at approximately USD 3.1 billion and is anticipated to grow at a robust compound annual growth rate (CAGR) of 6.8% through 2032. The burgeoning demand for these coatings across diverse applications, coupled with technological advancements and a strong emphasis on sustainability and performance,โ€ฆ
Hard Coatings Market Experiencing Strong Demand for Oxide and Carbon-Based Coatings
Hard Coatings Market Experiencing Strong Demand for Oxide and Carbon-Based Coati โ€ฆ
The hard coatings market is undergoing remarkable growth, with its value estimated at USD 893.3 million in 2023 and anticipated to surge to USD 1,599.7 million by 2033. This substantial increase, driven by a compound annual growth rate (CAGR) of 6.0% over the forecast period, underscores the rising demand and critical role of hard coatings across diverse industries. Known for their outstanding hardness, durability, and wear resistance, these coatings areโ€ฆ
Microreactor Technology Market is experiencing the latest trends and undergoing comprehensive industry analysis, according to Fact.MR.
Microreactor Technology Market is experiencing the latest trends and undergoing โ€ฆ
Microreactor technology, celebrated as a transformative force in chemical processing and manufacturing, has gained significant traction across diverse industries. Known for its compact design and efficient processing capabilities, this innovative approach offers numerous advantages over conventional methods. The microreactor technology market is poised for substantial growth, driven by its applications in pharmaceuticals, chemicals, and sustainable energy production. Key Market Players and Innovations: Several prominent players in the microreactor technology market are activelyโ€ฆ
Compressed Air Dryer Market is Growing with Demand from Industrial Machinery and Automotive Sectors for More Effective Solutions.
Compressed Air Dryer Market is Growing with Demand from Industrial Machinery and โ€ฆ
The global compressed air dryer market is currently witnessing substantial growth, fueled by increasing industrialization and a growing demand for efficient air compression solutions across various sectors. This article explores the current market landscape, key drivers, regional insights, and future prospects for the compressed air dryer industry. In 2022, the global compressed air dryer market was valued at approximately USD 3.5 billion. Projections suggest a robust compound annual growth rate (CAGR)โ€ฆ

All 5 Releases


More Releases for Constipation

Constipation Treatment Market Segmented by Application,Technology
Constipation treatment market is segmented on the basis of type, treatment, method of administration, and end use. By type, the global constipation treatment market has been categorized into chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC). On the basis of treatment, the global constipation treatment market has been categorized into pharmacological treatment and non-pharmacological treatment, which comprises bowel training for constipation relief, fluid intake,โ€ฆ
Constipation Treatment Market: Views Sought On New Approach
High prevalence rate in North America due to increasing adoption of unhealthy lifestyle characterized by growing consumption of fast food is leading to increasing obesity and other related health issues. This inadvertently leads to high incidence rate of constipation in the region. According to the American Society of Interventional Pain Physicians, the U.S. accounts for around 80% of the global opioids consumption. According to an article published in the American Gastroenterologicalโ€ฆ
Constipation Treatment Market Opportunity Analysis, 2018-2026
Constipation is a disorder that causes issues related to clearing of the bowels and usually leads to hardened feces. It is especially prevalent among the elderly and women. Common symptoms of constipation include lumpy or hard stools, lower abdominal discomfort, straining to have bowel movements, feeling of blockage in rectum that prevents bowel movements, and infrequent bowel movements. Factor that can lead to constipation are aging, dehydration, little or noโ€ฆ
Constipation Pharmaceutical and Healthcare Pipeline Review H1
Summary Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxativesโ€ฆ
Opioid Induced Constipation Treatment Market
Opioids are medications that work on opioid receptors in order to generate morphine-like effects. These are mainly used therapeutically to relieve pain and are often abused by individuals addicted to them. Opioids comprises opiates, a conventional name that points to drugs that are derivatives of opium, including morphine. Constipation means bowel actions that are sporadic or hard to go by. The fecal matter is often dry and hard. Some ofโ€ฆ
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipationโ€ฆ